Systematic Review And Meta-analysis Of Target Terapies For The Treatment Of Metastatic Renal Cancer

Objectives: At present there are several drugs for the treatment of advanced renal cell carcinoma (ARCC). The main objective of this work was to perform a systematic review (SR) and meta-analysis (MA) of clinical randomized studies that compared target cell therapies (TCT). Materials and Methods: SR identified clinical randomized trials that compared TCT versus interferon-alpha in the treatment of patients with ARCC. In order to analyze efficiency, it was evaluated free-survival progression (FSP), total survival (TS) and response rate (RR). Results: In relation to first line treatment, seven studies of TCT were identified using sunitinib, sorafenib, bevacizumab and temsirolimus; and two studies with sorafenib and everolimus for second line treatment. Relative risk (RRi) of MA for FSP of first line therapies was: 0.83, CI = 0.78-0.87, I2 = 94% and p < 0.00001. Best results of RR of specific FSP among studies were: 0.38, sunitinib, CI = 0.25-0.58, bevacizumab, 0.62, CI = 0.47-0.83; and temsirolimus, 0.78, CI = 0.70-0.87. MA didn't show any benefit regarding TS of first line treatment of all analyzed drugs. As for RR significant results were: sunitinib, 3.83 CI = 2.86-5.12; bevacizumab, 2.52 CI = 1.78-3.57 and bevacizumab, 1.97 CI = 1.43-2.71. Conclusions: For first line treatment, sunitinib was the most effective TCT in relation to FPS; there was no alteration of TS and RR was small but significant for sunitinib and bevacizumab. Available studies could not conclude any results for second line treatments.396768778Fisher, R.I., Rosenberg, S.A., Fyfe, G., Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma (2000) Cancer J Sci Am, 6 (SUPPL. 1), pp. S55-S57McDermott, D.F., Regan, M.M., Clark, J.I., Flaherty, L.E., Weiss, G.R., Logan, T.F., Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients withmetastatic renal cell carcinoma (2005) J Clin Oncol, 23, pp. 133-141. , Erratum in: J Clin Oncol. 200523: 2877Motzer, R.J., Murphy, B.A., Bacik, J., Schwartz, L.H., Nanus, D.M., Mariani, T., Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma (2000) J Clin Oncol, 18, pp. 2972-2980Yang, J.C., Sherry, R.M., Steinberg, S.M., Topalian, S.L., Schwartzentruber, D.J., Hwu, P., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer (2003) J Clin Oncol, 21, pp. 3127-3132Higgins, J.P.T., Green, S., (2008) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2, , http://www.cochrane-handbook.org, [updated September 2009]: The Cochrane Collaboration(2008), http://ims.cochrane.org/home, The Nordic Cochrane Centre. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Cochrane CollaborationHiggins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses (2003) BMJ, 327, pp. 557-560Cella, D., Li, J.Z., Cappelleri, J.C., Bushmakin, A., Charbonneau, C., Kim, S.T., Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial (2008) J Clin Oncol, 26, pp. 3763-3769Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (2007) Lancet, 370, pp. 2103-2111Escudier, B., Szczylik, C., Hutson, T.E., Demkow, T., Staehler, M., Rolland, F., Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma (2009) J Clin Oncol, 27, pp. 1280-1289. , Erratum in: J Clin Oncol. 200927: 2305Escudier, B., Bellmunt, J., Négrier, S., Bajetta, E., Melichar, B., Bracarda, S., Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysisof overall survival (2010) J Clin Oncol, 28, pp. 2144-2150Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma (2007) N Engl J Med, 356, pp. 2271-2281Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma (2007) N Engl J Med, 356, pp. 115-124Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Oudard, S., Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cellcarcinoma (2009) J Clin Oncol, 27, pp. 3584-3590Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Ou, S.S., Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 (2008) J Clin Oncol, 26, pp. 5422-5428Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Archer, L., Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cellcarcinoma: final results of CALGB 90206 (2010) J Clin Oncol, 28, pp. 2137-2143Yang, S., de Souza, P., Alemao, E., Purvis, J., Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha (2010) Br J Cancer, 102, pp. 1456-1460Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M., Sorafenib in advanced clear-cell renal-cell carcinoma (2007) N Engl J Med, 356, pp. 125-134. , Erratum in: N Engl J Med. 2007357: 203Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2008) Lancet, 372, pp. 449-456Bukowski, R., Cella, D., Gondek, K., Escudier, B., Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renalcancer (2007) Am J Clin Oncol, 30, pp. 220-227. , Sorafenib TARGETs Clinical Trial GroupSternberg, C.N., Davis, I.D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial (2010) J Clin Oncol, 28, pp. 1061-1068Rexer, H., First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2-AN 33/11)] (2012) Urologe A, 51, pp. 724-726Rini, B.I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T.E., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (2011) Lancet, 378, pp. 1931-1939. , Erratum in: Lancet. 2012380: 1818Nosov, D.A., Esteves, B., Lipatov, O.N., Lyulko, A.A., Anischenko, A.A., Chacko, R.T., Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cellcarcinoma (2012) J Clin Oncol, 30, pp. 1678-168